Chemical Formula: C294H342F13N107Na28O188P28[C2H4O]2n
Molecular Weight: 535.5031
Assay/Purity: Typically NLT 98%
Pegaptanib is indicated for the treatment of endovascular/wet age-related macular degeneration and diabetic macular edema.
As a polynucleotide aptamer Pegaptanib binds specifically to VEGF 165, which is the protein that elicits angiogenesis (and increases permeability.
Mode of Action:
Pegaptanib is a modified oligonucleotide that binds to the major pathological VEGF isoform, extracellular VEGF165, with a high affinity.
In animal studies Pegaptanib slowly absorbs into the body via an intravenous injection into the eye. Clinical data shows that Pegaptanib is metabolized by both the endo- and exonucleases.
Pegaptanib has not been studied for toxicity in pregnant women or the pediatric population. The majority of adverse effects related to Pegaptanib are and minor. A small number of patients report non-ocular events, such as headache when the procedure occurs, but this is uncommon. Pegaptanib should not be used if the patient has a periocular or ocular infection.
Expert Opinion on Drug Metabolism & Toxicology (Impact Factor: 2.93). 05/2014; DOI: 10.1517/17425255.2014.922543Clinical ophthalmology (Auckland, N.Z.) 02/2015; 9:323-35. DOI:10.2147/OPTH.S74050Acta Ophthalmologica .4 JAN 2015. DOI: 10.1111/aos.12603.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs